The working basis was developed for scientific, pharmaceutical and clinical researchers as well as for the quality control of biological agents and offers deep insights into the functional or pathological proteoforms or oligonucleotides. Multimodal eXd trapping with electron energy control, ion accumulation and reaction time regulation is a fundamental innovation of the new platform. This also enables Collision Induced Unfolding (CIU) as an activation method for the proteins, increasing the value of proteoform CCS information, followed by multiple electron-based (ECD, EID) and collision-based (CID) fragmentation techniques.
The flexible top-down capability of the mass spectrometer enables the identification of rare, abnormal proteoforms. These are structurally altered versions of proteins resulting from genetic mutations, alternative splicing or post-translational modifications. They deviate from normal physiological forms, disrupt protein function and cause misfolding or aggregation. As a result, they often play a crucial role in diseases, including cancer, neurodegeneration, cardiovascular diseases and autoimmune diseases.
The mass spectrometer is supported by the Omniscape software. It is supplied with the new Neos offline nano-ESI for low infusion flow rates. The NEOS source works with coated and uncoated emitters. In addition, the mass spectrometer retains the sensitivity of the Tims-TOF Ultra 2 for nLC-dia-PASEF high-throughput bottom-up 4D proteomics.